Status:
COMPLETED
Clinical Trial to Evaluate the Efficacy and Safety of CKD-386
Lead Sponsor:
Chong Kun Dang Pharmaceutical
Conditions:
Dyslipidemia Patients With Hypertension
Eligibility:
All Genders
19+ years
Phase:
PHASE3
Brief Summary
Clinical Trial to Evaluate the Efficacy and Safety of CKD-386
Eligibility Criteria
Inclusion
- Subjects are diagnosed with Dyslipidemia Patients with Hypertension or are being administered anti-hypertension and anti-hypertension drugs after diagnosis.
- Subjects who agreed to participate in this clinical trial voluntarily.
Exclusion
- Subjects who were satisfied specific blood pressure levels that measured at screening period.
- Subjects who were satisfied specific lipid levels that measured at screening period.
- Subjects who cannot participate in a clinical trial based on the PI's judgment.
Key Trial Info
Start Date :
August 29 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 18 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04312698
Start Date
August 29 2019
End Date
June 18 2021
Last Update
July 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yonsei University Medical Center Severance Hospital
Seoul, South Korea